News
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: HomeServe plc
Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc
Form 8.3 - The Vanguard Group, Inc.: Countryside Partnerships plc
Form 8.3 - The Vanguard Group, Inc.: ContourGlobal plc
Form 8.3 - The Vanguard Group, Inc.: Capricorn Energy plc
Form 8.3 - The Vanguard Group, Inc.: Capital & Counties Properties plc
Form 8.3 - The Vanguard Group, Inc.: Brewin Dolphin Holdings plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Rights and Issues Investment Trust PLC: TEN-Tender Offer Clarification
DGAP-News: niiio subsidiary PATRONAS Collaborates with Temenos Multifonds to Deliver Holistic ‘Best-of-Breed’ Solution for Fund Administration
Aroundtown SA: Release of a capital market information
Form 8.3 - Maitland Institutional Services Limited: Re Euromoney Institutional Investor plc
Rights and Issues Investment Trust PLC: Net Asset Value(s)
Water Leaders to Accelerate Action Towards UN Sustainable Development Goals at IWA World Water Congress 2022
There are 2.3 billion people who now live in water-stressed countries and 18 million people risk being displaced by floods every year1. Against this backdrop, global water technology company Xylem
Hardman & Co Q&A on Surface Transforms (SCE): It's all in the detail
Chelverton UK Dividend Trust plc: Net Asset Value(s)
EQS-News: Yandex announces completion of News and Zen divestment and acquisition of Delivery Club
Baloise to host ‘burnout prevention’ online event for entrepreneurs
Sensorion Receives Positive Opinion for Orphan Drug Designation for OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss From the European Medicine Agency
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024
Regulatory News:
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces positive confirmatory data